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Background and Objectives
Peripheral blood stem cells (PBSC) following reduced intensity conditioning (RIC) are
being increasingly used for allogeneic transplantation in multiple myeloma. The pur-
pose of this study was to compare outcome of patients transplanted with either PBSC
or bone marrow (BM) following RIC or myeloablative conditioning (MAC).
Design and Methods
Data from 1,667 patients who had received an allogeneic identical sibling donor
transplant for multiple myeloma from 1994 to 2003 were analyzed. Comparisons
were made between results of PBSC and BM transplants after conditioning with RIC
or MAC. 
Results
The engraftment rate was faster with PBSC than with BM (median: 14 and 18 days
for neutrophils and 15 and 25 days for platelets respectively) irrespectively of whether
RIC or MAC was used. The incidence of acute graft-versus-host disease (GVHD) did
not differ significantly between the groups while chronic GVHD was more prevalent in
PBSC recipients irrespectively of whether they had RIC or MAC. Non-relapse mortality
did not differ between PBSC and BM recipients, but was significantly higher in those
treated with MAC than in those given RIC irrespectively of the cell source. The
relapse/progression rate did not differ between PBSC and BM recipients, but was sig-
nificantly higher in those given RIC, irrespectively of the cell source. There was no sig-
nificant difference in overall or progression-free survival between patients given PBSC
or BM transplants.  
Interpretation and Conclusions
Although transplantation of PBSC is associated with faster engraftment and more fre-
quent chronic GVHD, overall survival, non-relapse mortality, relapse/progression and
progression-free survival are similar to those following BM transplants. However both
PBSC and BM transplants are associated with lower non-relapse mortality, lower
response rate and higher relapse/progression if RIC is used instead of MAC.
Key words: peripheral blood stem cell trasplantation, bone marrow trasplantation,
reduced intensity conditioning, myeloablative conditioning, multiple myeloma.
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The European Group for Blood and MarrowTransplantation (EBMT) centers have used peripher-al blood stem cells (PBSC) for allogeneic transplanta-
tion in multiple myeloma since 1994.1 The number of trans-
plants performed with PBSC increased rapidly and since
1998 the majority of transplants have been performed with
PBSC. Previous studies indicated that the overall survival
of myeloma patients transplanted with PBSC and BM1 is
similar in agreement with some,2-10 but in contrast to other
studies in leukemia and other hematologic malignancies
indicating better results with PBSC11,12 or with BM.13
Engraftment in myeloma was found to be faster with PBSC
but this has not translated into less treatment-related mor-
tality (non-relapse mortality=NRM) or into improved sur-
vival.1 The incidence of acute graft-versus-host disease
(GVHD) is similar, while chronic GVHD appears to be more
frequent with PBSC.1 These data corroborate observations
in other hematologic disorders. However, these studies
were performed in patients who have received high-dose
myeloablative conditioning (MAC) regimens before trans-
plantation. Since 1997, reduced-intensity conditioning (RIC)
transplantation has been used in patients with myeloma,
and from 2001 such transplants were more frequently
reported to the EBMT registry than standard MAC trans-
plants. Although recent investigations have shown a low
treatment-related mortality with RIC14,15 in multiple myelo-
ma, registry studies within the EBMT have also shown that
the relapse rate among patients given RIC is significantly
higher than that among patients given MAC.16 Since the
increasing use of PBSC for transplantation paralleled the
increased use of RIC, with some years delay,  we have
undertaken a retrospective registry study comparing the
outcome of patients transplanted with PBSC or bone mar-
row (BM) following RIC or MAC.
Design and Methods
Patients
The population study consisted of patients reported to
the EBMT registry, who had received a first allogeneic HLA
identical sibling donor transplant between 1994 and 2003
and for whom information was available on  basic variables,
such as sex and age, as well as source of stem cells. There
were 1,667 multiple myeloma patients who fulfilled these
criteria: 1,179 had received PBSC and 488 BM. Table 1
shows the characteristics of these patients and their trans-
plants. There were some differences in prognostic factors
between the two groups of patients. Patients who received
PBSC were significantly older than those who received BM
and they had more frequently received autologous trans-
plants before the allogeneic transplant. The year of trans-
plant was more recent for PBSC recipients than for BM
recipients. Total body irradiation in the conditioning regi-
men and T-cell depletion were used less frequently. Other
factors, such as stage at diagnosis, female donor to male
recipient, number of lines of previous chemotherapy, and
response status at conditioning were similar. 
The study was approved by the Ethics Committee of the
Karolinska Institutet. Informed consent was obtained locally
according to national regulations.
Table 1. Patient and transplant characteristics. 
Variable Data PBSC BM p
available Number % Number % value
(%)
Age (years) 100
0-45 339 29 238 49 <0.0001
>45 840 71 250 51
Gender 100
Male 748 63 288 59 0.09
Female 431 37 200 41
Type of myeloma 91
IgG 615 57 259 59 0.38
IgA 219 21 90 21
Light chain 184 17 61 14
Other 55 5 28 6
Stage at diagnosis 71
I 102 12 37 12 0.78
II 178 21 72 22
III (IIIB, % of III) 584 67 (17) 211 66(19)
Number of prior 49
treatment regimens
0-1 314 62 186 61 0.82
2-3 196 38 120 39
Number of prior 100
autotransplants
0 693 59 413 84 <0.0001
1 401 34 62 13
2 or  more 85 7 13 3
Response status 90
at conditioning
CR 143 13 75 17 0.01
PR 617 58 236 54
No change 120 11 67 15
Relapse/progression 100 187 18 60 14
Year of transplant
1994-95 14 1 126 26 <0.001
1996-97 97 8 123 25
1998-99 228 19 120 25
2000-01 394 33 74 15
2002-03 446 38 45 9
Time from diagnosis to 
transplant (months) 97
0-12 482 42 282 59 <0.001
>12 667 58 193 41
Conditioning 85
RIC 596 60 52 12 <0001
MAC 401 40 369 88
TBI in conditioning 97
No 620 54 134 28 <0.0001
Yes 520 46 337 72
T-cell depletion 88
None 712 67 236 58 <0.0001
In vivo 9 1 5 1
Ex vivo 129 12 126 31
Other 214 20 43 10
Female donor 97
for male recipient 
No 828 72 359 75 0.26
Yes 316 28 119 25
Total cell dose 62
given×106/kg
Low (≤2.0) 20 4 69 57 <0.0001
Intermediate 113 22 33 27
(2.0-4.0)
High (>4.0) 376 74 20 13
CD34+ dose 59
given x 106/kg
Low (≤2.0) 50 12 155 57 <0.0001
Intermediate (2.0-4.0) 29 7 81 30
High (>4.0) 339 81 34 13
HLA-identical allogeneic transplantation for myeloma
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Conditioning regimens 
The type of conditioning was known for 1,418 cases (648
RIC and 770 MAC). In the absence of a universally agreed
definition of RIC the local centers’ definition of RIC and
MAC was used. The main types of RIC and MAC used are
presented in Table 2.  
T-cell depletion
T-cell depletion was defined as ex vivo or in vivo. Ex vivo T-
cell depletion included all kinds of  T-cell depletion of the graft
before stem-cell infusion. In vivo depletion included all kinds
of monoclonal antibody therapy, antilymphocyte globulin
(ALG), antithymocyte globulin (ATG)  or serotherapy given
in association with the conditioning regimen. Other T-cell
depletion was defined as combinations of both in vivo and in
vitro T-cell depletion or combinations of any of these with T-
cell depleting drugs.
Statistics 
Comparisons between groups were made using the χ2 test
for categorical data, and the Mann-Whitney or Kruskall-
Wallis test for continuous data. Probabilities of overall and
progression-free survival were calculated using the Kaplan-
Meier method, and unadjusted comparisons were made
using the log-rank test. For outcomes with competing risks,
NRM and relapse/progression, and time to engraftment (with
death without engraftment as a competing risk) probabilities
were estimated using the cumulative incidence non-paramet-
ric estimator, and were compared by the Gray test.
Multivariate Cox models were used to assess differences for
overall survival, progression-free survival, relapse-progres-
sion, NRM and engraftment hazards. As the type of condi-
tioning regimen was a potentially strong confounder of the
effect of the source of cells, the role of source was assessed in
the sub-population of patients for whom the type of condi-
tioning was known (patients with available data n=1418;
with missing data n=249), testing differences between PBSC
and BM recipients within those given RIC or MAC. It was
checked that the group of patients for whom information on
this type of conditioning was lacking behaved similarly to the
other groups with respect to outcomes, thus indicating the
absence of a selection bias. A multivariate analysis of the out-
comes was performed in order to assess net differences
observed in PBSC and BM recipients. Adjustment factors
were selected among: calendar period, age, patient’s sex,
patient-donor gender mismatch, time interval between diag-
nosis and transplantation, stage at diagnosis, β2 microglobulin
level at diagnosis, response status at conditioning, response
status at transplantation, number of lines of therapy, number
of previous autologous transplants, total body irradiation dur-
ing conditioning, T-cell depletion, and the dose of CD34-pos-
itive cells given. In the case of a high number of patients with
missing values for a certain variable, those with missing val-
ues were considered as a separate group, and it was checked
that this group behaved as a mixed group, such that it was
possible to estimate net effects for the main factor of interest
without losing information. 
All analyses were performed in SAS 8.02; the macro CIN
created by the Departments of Biostatistics of St. Jude’s
Children Research Hospital in Memphis was used to analyze
competing risks. All reported p-values are from two-sided
tests. Confidence intervals (CI) refer to 95% boundaries. 
Results
Engraftment and graft failure 
Engraftment was faster with PBSC than with BM for both
neutrophils  and platelets. The median time to neutrophil
engraftment was 14 and 18 days (p<0.0001) and to platelet
engraftment 15 and 25 days (p=0.0002) for PBSC and BM
recipients, respectively. 
The faster engraftment for both neutrophils and platelets
with PBSC as compared to BM was independent of the con-
ditioning regimen. In multivariate analysis, the HR of neu-
trophil engraftment for PB versus BM was 1.58 (p=0.027) and
1.46 (p=0.0002) in patients given RIC and MAC, respectively;
for platelet engraftment it was 2.10 (p=0.007) and 1.78
(p<0.0001), respectively.
The overall graft failure rate with PBSC and BM in the  RIC
group was 2.9% and 9.8%  (p=0.027), respectively, and in the
MAC group 6.8% and 4.8% (p=0.273), respectively. Thus
with RIC it appeared that PBSC could decrease the risk of
graft failure after RIC, whereas it did not seem to be impor-
tant for the risk of graft failure whether PBSC or BM was used
following MAC. Seventy-one patients (4.3%) died without
engraftment at a median time of 0.6 months after transplan-
tation. There was no obvious difference between the groups.
Response to transplantation
Response to transplantation is shown in Table 3 for PBSC
and BM recipients given RIC or MAC. The overall response
rates according to Blade´s criteria  (complete response [CR] +
partial response [PR]) with RIC  (61%) and MAC (65%) were
similar. However the CR rate was higher with MAC (42%)
than with RIC (32%). This was irrespective of the pretrans-
plant response status. Thus the CR rate in patients who were
Table 2. Conditioning regimens.
Reduced intensity conditioning
Conditioning regimen Number of patients Per cent
Fludarabine + TBI 105 16.2
Fludarabine + Melphalan 137 21.1
Fludarabine + Busulphan 113 17.4
Other 293 45.2
Total 648 100
Myeloablative conditioning
Conditioning regimen Number of patients Per cent
Melphalan + TBI 177 23.0
Cyclophosphamide + TBI 216 28.1
Busulphan + cyclophosphamide 51 6.6
Other 326 42.3
Total 770 100
TBI: total body irradiation.
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PBSC or BM cells in RIC or MAC allogeneic transplantation for myeloma
in PR pretransplant was 43% with PB-MAC, and 40% with
BM-MAC, but only 28% with PB-RIC and 17% with BM-
RIC. Among the patients with progressive/relapsed disease
pretransplant,  the CR rates were 38% in the PB-MAC group
and 21% in the PB-RIC group while the numbers of patients
were too low for a comparison of the BM-RIC and BM-MAC
groups. 
There was no significant difference in CR rate between
PBSC or BM recipients given MAC (42% and 43% respec-
tively), while the overall response rate was somewhat lower
with PBSC than with BM (p=0.023). In the RIC group there
appeared to be an advantage from using PBSC (CR rate 34%
with PBSC and 16% with BM). The  overall response rate
(CR+PR ) of PBSC recipients given RIC was 62% versus 51%
among BM recipients (p=0.047). Thus the response was
worse with RIC than with MAC, but could be improved
somewhat by using PBSC instead of BM.
Non-relapse mortality
There was no significant difference in NRM between PBSC
and BM recipients irrespectively of whether reduced intensi-
ty or myeloablative conditioning was used (Figure 1).
However, NRM was lower with RIC than with MAC, for
both PBSC and BM recipients. NRM at day 100 was 11% and
17% with PBSC and 6% and 18% with BM with RIC and
MAC, respectively. The lack of significant differences was
confirmed in multivariate analysis (p=0.4 and p=1.0 for RIC
and MAC, respectively). Thus, the more rapid engraftment
rate with PBSC did not translate into lower NRM after either
RIC or MAC. 
Relapse rate and progression-free survival
The overall relapse/progression rate (Figure 2) appeared to
be higher among PBSC recipients than among patients trans-
planted with BM, but this turned out to be due to the higher
number of RIC transplants in the PBSC group as compared to
the MAC group. The relapse rate was significantly higher fol-
lowing RIC than after MAC, but there was no significant dif-
ference between the rates in PBSC and BM recipients within
either the RIC or MAC group.  These results were confirmed
in the multivariate analysis, in which no significant differ-
ences were found in progression-free survival or relapse/pro-
gression hazard between the PBSC-RIC and BM-RIC groups
(p=0.37 and p=0.55 respectively) or between the PBSC-MAC
and BM-MAC groups (p=0.07 with HR=1.21 and p=0.08
with HR=1.30, respectively). A weak trend for a poorer pro-
gression-free survival and higher relapse rate following PBSC-
MAC transplants did not translate into poorer survival with
PBSC, as shown later.
Table 3. Response rate.
Response rate following RIC
Best response to transplantation Total
Source of CR PR No CR-PR/Progression number of
stem cells Number of Number of Number of patients
patients (%) patients (%) patients (%)
PBSC 178 (33.5) 152 (28.6) 201 (37.9) 531
BM 8 (16.3) 17 (34.7) 24 (49.0) 49
Total 186 (32.1) 169 (29.1) 225 (38.8) 580
Response rate following MAC
Best response to transplantation Total
Source of CR PR No CR-PR/Progression number of 
stem cells Number of Number of Number of patients
patients (%) patients (%) patients (%)
PBSC 139 (41.9) 63 (19.0) 130 (39.2) 332
BM 135 (42.5) 85 (26.7) 98 (30.8) 318
Total 274 (42.2) 148 (22.8) 228 (35.1) 650
Figure 1. Non-relapse mortality (NRM) in PBSC and BM recipients
following RIC and MAC. The overall NRM was lower after RIC than
after MAC (p=0.0008). However there was no significant differ-
ence in NRM between PBSC and BM recipients within the RIC
group (p=0.428) or the MAC group (p=0.970). 
Figure 2. Relapse/progression rate in PBSC and BM recipients
after RIC or MAC. The overall relapse/progression rate was signif-
icantly higher after RIC than after MAC (p<0.0001). However there
was no significant difference in the relapse rate between PBSC
and BM recipients within the RIC group recipients (p=0.547) or the
MAC group (p=0.077).   
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Overall survival
There was no significant difference in overall survival
between PBSC and BM recipients (Figure 3). The median
overall survival was 30 months and 32 months for PBSC  and
BM recipients, respectively, and the 5- and 7-year survival
rates were 33% and 30%, and 38% and 36% for PBSC and
BM recipients, respectively. Differences in overall survival
between PBSC and BM recipients were confirmed to be non-
significant in the multivariate analysis (p=0.33 in the RIC
group and p=0.95 in the MAC group).  The overall survival of
both PBSC and BM recipients was independent of the use of
RIC or MAC. Thus, the lower NRM with RIC was counter-
balanced by the higher relapse rate within both the PBSC and
BM groups, resulting in a similar overall survival.
Graft-versus-host disease
There was no apparent difference in acute GVHD between
PBSC and BM recipients. Grade II-IV GVHD was seen in
34.7% of patients receiving PBSC and in 39.5% of those
receiving BM (p=0.08). However, overall chronic GVHD was
more frequent with PBSC (54.0%) than with BM (41.4%)
(p=0.001), while there was no significant difference in exten-
sive chronic GVHD between the two groups (25.0% and
23.1% in the PBSC and BM groups, respectively; p=0.58).
When PBSC and BM recipients were analyzed separately
according to whether they were given RIC or MAC, the find-
ings were similar. Although there was a weak tendency for
better survival in patients with chronic GVHD, assuming that
the chronic GVHD occurred within 1 year after transplanta-
tion and adjusting for the fact that patients had survived for
at least 1 year, the difference was not statistically significant
(p=0.129). Among the population of patients for whom the
type of conditioning was known, sufficient information on
chronic GVHD was available for only 461. Therefore, further
subgroup analysis could not be done.
Discussion
The EBMT centers have used PBSC in allogeneic transplan-
tation for multiple myeloma  since 1994. A previous EBMT
study showed that results of allogeneic transplantation
improved dramatically from 1994, i.e. in parallel with the
increasing use of PBSC.1 The improvement was due to a
reduction in NRM, but this did not appear to be the result of
the use of PBSC. No improvement in relapse rate was seen
with either PBSC or BM, but the observation period may not
have been long enough to reveal a difference.
RIC transplantation did not start until 1998. Thus it
seemed important to compare outcomes of PBSC and BM
transplants in patients given RIC and MAC separately, since
an effect of hematopoietic cell source may be different in the
two conditioning regimens considering that more chronic
GVHD was seen with PBSC in the previous investigation.
During the period  2002-2003, 91% of the allogeneic trans-
plants in myeloma recipients reported to the EBMT registry
were performed with PBSC as compared to 66% during the
period 1998-99. During the same time the use of RIC trans-
plants increased from 37% to 75%  Thus, with a few years
delay there has been a parallel increase in PBSC and RIC
transplants in myeloma patients reported to EBMT centers.  
In this study we found that despite the slower engraftment
of RIC transplants compared to MAC transplants, the more
rapid engraftment rate with  PBSC as compared to  BM was
similar in both RIC and MAC recipients. The overall NRM
mortality was similar in PBSC and BM recipients but was
heavily influenced by the use of RIC or MAC. Thus, as
shown previously, the NRM in myeloma was lower with
RIC than with MAC14-16 but we have now shown that it is
similar for PBSC and BM recipients within each conditioning
group. 
The overall higher relapse rate with PBSC as compared to
BM was almost entirely due to the concomitant use of RIC
with increasing use of PBSC. Within the RIC groups there
was no significant difference between PBSC and BM recipi-
ents. However, within the MAC group the multivariate
analyses indicated a weak trend to PBSC being associated
with a slightly higher relapse rate and poorer progression-free
survival; however, this did not translate into a poorer overall
survival. 
Overall survival was similar in PBSC and BM recipients,
corroborating our previous results observed in patients given
MAC.1 This lack of difference in overall survival was also
present when patients were separated into RIC and MAC
groups, since the lower NRM with RIC was offset by the
higher relapse rate, irrespectively of whether PBSC or BM
was used for the transplant.
As shown, there was no significant difference in acute
GVHD disease depending on whether PBSC or BM were
used, while the incidence of chronic GVHD was higher
with PBSC.1 This finding corroborates results in other
hematologic disorders.3,6-9,17 In the present study this differ-
ence seemed to be more pronounced in patients given
RIC, perhaps due to a somewhat higher T-cell depletion
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Figure 3. Overall survival of PBSC and BM recipients. There was
no significant difference in overall survival between PBSC and BM
(p= 0.505) irrespectively of whether they received RIC (p=0.331)
or MAC (p=0.951). 
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rate in BM-RIC (58%) than in PBSC-RIC (30%) trans-
plants. There may also have been an impact of the some-
what higher median age and later transplants in the PBSC
group (both with RIC and with MAC) than in the BM
group. Despite the relatively long follow-up, the higher
rate of chronic GVHD following PBSC-RIC did not seem
to translate into a lower relapse rate than that following
BM-RIC. However, the number of BM-RIC transplants
was small (n=52), as compared to the PBSC transplants
(n=596), so it could be difficult to detect a significant dif-
ference. 
Allogeneic transplantation in myeloma patients is still
hampered by high transplant-related mortality, irrespective of
the use of  PBSC or BM. Although the use of RIC is associat-
ed with a lower NRM than that with MAC transplants,
unfortunately this does not translate into better overall sur-
vival, irrespectively of whether PBSC or BM is used, due to
the higher relapse rate following RIC. 
Thus new strategies need to be explored for myeloma
patients; for example, new targeted and immunomodulatory
drugs (IMID) in the conditioning in RIC-like regimens, to
improve cell killing, may be one approach. The relapse rate
following MAC allogeneic transplantation in myeloma is
lower than that after autologous transplantation.16 Very few
myeloma patients treated with MAC allogeneic transplants
relapse or progress between 5 and 7 years after transplanta-
tion. Whether this is also true for RIC transplants remains to
be seen. The recently closed prospective EBMT study com-
paring autologous and allogeneic RIC transplantation based
on genetic randomization may give an answer (Björkstrand et
al., unpublished data). Prospective studies using unrelated
donors and RIC conditioning are also warranted and being
planned (Niederwieser et al.).
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